Foscenvivint | PRI-724;C-82 prodrug;ICG-001 analog | Epigenetic Reader Domain | β-catenin

首页 / / / / Foscenvivint

Foscenvivint 99%+

货号：A650610 同义名： PRI-724;C-82 prodrug

PRI-724 is a selective inhibitor of the CBP/β-catenin interaction.

Foscenvivint 化学结构
CAS号：1422253-38-0

Foscenvivint 3D分子结构
CAS号：1422253-38-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Foscenvivint 纯度/质量文件产品仅供科研

货号：A650610 标准纯度： 99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

表观遗传阅读框亚型比较

产品名称	BET ↓ ↑	bromodomain ↓ ↑	BRPF ↓ ↑	CBP/beta-catenin ↓ ↑	p300/CBP ↓ ↑	其他靶点	纯度
MS436	++ BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM						99%+
CPI-203	+++ BRD4, IC50: 37 nM						99+%
GSK1324726A	+++ BRD2, IC50: 31 nM BRD4, IC50: 22 nM						99%+
PFI-1	++ BRD2, IC50: 98 nM BRD4, IC50: 0.22 μM						98%
Apabetalone	+ BD2, IC50: 0.51 μM						99%
(+)-JQ1	+++ BRD4 (2), IC50: 33 nM BRD4 (1), IC50: 77 nM						98%
I-BET151	+ BRD3, IC50: 0.25 μM BRD4, IC50: 0.5 μM						98%
Molibresib	+++ BET proteins, IC50: 35 nM						99%+
I-BRD9	+++ BRD4, pIC50: 5.3 BRD9, pIC50: 7.3						99%+
BI-7273	++++ BRD9, IC50: 19 nM BRD7, IC50: 117 nM						99+%
Pelabresib	+++ BRD4-BD1, IC50: 39 nM						98%
ARV-825	+++ BRD4 BD1, Kd: 90 nM BRD4 BD2, Kd: 28 nM						99%+
Birabresib							99%+
BI 2536	+++ BRD4, Kd: 37 nM					c-Myc	99%+
Bromosporine	++ BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM	++++ CECR2, IC50: 17 nM					99%+
XMD8-92	++ BRD4 (1), Kd: 170 nM						99%+
Mivebresib	✔						99%+
BI-9564	++++ BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM	++ CECR2, Kd: 77 nM					98%
AZD5153 6-Hydroxy-2-naphthoic acid	++++ FL-BRD4, IC50: 5 nM						99%+
PLX51107	++++ BRD3 BD1, Kd: 2.1 nM BRD4 BD2, Kd: 1.7 nM						99%+
FL-411	+ BRD4(1), IC50: 0.43 μM						99%+
ABBV-744	✔						99%+
dBET6	++++ BRD4, IC50: 14 nM						99%+
dBET1	++++ BRD4, IC50: 20 nM						99%+
MZ1	++++ Brd3(BD2), Kd: 13 nM Brd2(BD2), Kd: 62 nM						99%+
dBET57	+ BRD4_BD1, DC50: 500 nM						99%+
SF2523	+ BRD4, IC50: 241 nM					DNA-PK	99%+
INCB054329	++++ BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM						99%
INCB-057643	✔						99%+
(E/Z)-ZL0420	+++ BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM						99%+
BMS-986158	✔						99%+
BRD4 Inhibitor-10	++++ BRD4-BD2, IC50: 41 nM BRD4-BD1, IC50: 5 nM						97%
A1874	✔						99%+
Y06036	++ BRD4 (1), Kd: 82 nM						99%+
Alobresib	✔					NF-κB	98%
ODM-207	✔						99%
GSK778	+++ BRD4-BD1, IC50: 143 nM BRD2-BD1, IC50: 75nM						97%
SRX3207	+ BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM					Syk	98%
GSK046	+++ BRD4_BD2, IC50: 214 nM BRD3_BD2, IC50: 98 nM						98%
GSK620	✔						97%
Thalidomide-NH-C4-NH-Boc	✔						98%
Trotabresib	✔						99%
NHWD-870	✔						98%
CFT8634	++++ BRD9, DC50: 3 nM						98%
GSK2801		++ BAZ2A, Kd: 257 nM BAZ2B, Kd: 136 nM					99%+
KG-501		✔					99%+
UNC 669		+ L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM					98%
PFI-3		+++ SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM					99%+
UNC1215		+++ L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM					99%+
EED226		++ EED, Kd: 82 nM PRC2, Kd: 114 nM					99%+
BRD9539		✔					98%
UNC926		+ L3MBTL1, Kd: 3.9 μM					99%
666-15		++ CREB, IC50: 81 nM					99%+
UNC6852		+ EED, IC50: 247 nM					98%
BAZ1A-IN-1		+ BAZ1A, Kd: 0.52 μM					99%+
PFI-4			++ BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM				99%+
OF-1			++ BRPF1B, Kd: 100 nM BRPF2, Kd: 500 nM				99%+
GSK-5959			++ BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2				99%
GSK6853			++++ BRPF1, pIC50: 8.1				99%+
NI-42			++++ BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM				99%+
E-7386				+++ CBP/beta-catenin, IC50: 0.0484 μM			97%
I-CBP112					++ CBP, Kd: 151 nM p300, Kd: 167 nM		98+%
Histone Acetyltransferase Inhibitor II					+ p300, IC50: 5 μM		98%
C646					+ p300/CBP, Ki: 400 nM		99%+
Anacardic Acid					+ PCAF, IC50: 5 μM p300/CBP, IC50: 8.5 μM		99%+
SGC-CBP30					++++ CREBBP, IC50: 21 nM EP300, IC50: 38 nM		99%+
Nordihydroguaiaretic acid					✔	HER2,IGF-1R	99%+
Curcumin					+ p300, IC50: ~25 μM	NF-κB,Ferroptosis,Nrf2	98%
PF-CBP1 HCl					++ CREBBP, IC50: 125nM p300/CBP, IC50: 363nM		97%
CPI-637					+++ CBP, IC50: 0.03 μM EP300, IC50: 0.051 μM		99%+
Foscenvivint					✔	β-catenin	99%+
A-485					++ p300 HAT, IC50: 0.06 μM		99%+
GNE-781	+ BRD4(1), IC50: 5100 nM				++++ CBP, IC50: 0.94 nM		98%
NEO2734	+++ BET, IC50: <30 nM				+++ p300/CBP, IC50: <30 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Foscenvivint 生物活性

靶点	p300/CBP
描述	PRI-724 is a selective inhibitor of the CBP/β-catenin interaction.

Foscenvivint 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01606579	Acute Myeloid Leukemia ... 展开 >> Chronic Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, Georgia ... 展开 >> Emory University / Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts University of Massachusetts Medical Center Worcester, Massachusetts, United States, 01655 United States, New Mexico New Mexico Cancer Care Alliance Albuquerque, New Mexico, United States, 87106 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210-1267 United States, Texas University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02195440	Hepatitis C Virus-infected Cir... 展开 >>rhosis 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Tokyo metropolitan Komagome Hospital Tokyo, Japan 收起 <<
NCT02413853	Colorectal Adenocarcinoma ... 展开 >> Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer 收起 <<	Phase 2	Withdrawn(Study drug supply is... 展开 >>sues) 收起 <<	November 2018	United States, California ... 展开 >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 收起 <<

Foscenvivint 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.52mL

0.30mL

0.15mL

7.59mL

1.52mL

0.76mL

15.18mL

3.04mL

1.52mL

Foscenvivint 技术信息

CAS号	1422253-38-0
分子式	C₃₃H₃₅N₆O₇P
分子量	658.641

别名	PRI-724;C-82 prodrug;ICG-001 analog
运输	蓝冰

存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01606579	Acute Myeloid Leukemia ... 展开 >> Chronic Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, Georgia ... 展开 >> Emory University / Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts University of Massachusetts Medical Center Worcester, Massachusetts, United States, 01655 United States, New Mexico New Mexico Cancer Care Alliance Albuquerque, New Mexico, United States, 87106 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210-1267 United States, Texas University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02195440	Hepatitis C Virus-infected Cir... 展开 >>rhosis 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Tokyo metropolitan Komagome Hospital Tokyo, Japan 收起 <<
NCT02413853	Colorectal Adenocarcinoma ... 展开 >> Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer 收起 <<	Phase 2	Withdrawn(Study drug supply is... 展开 >>sues) 收起 <<	November 2018	United States, California ... 展开 >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 收起 <<
NCT02828254	-		Completed	-	Japan ... 展开 >> Tokyo metropolitan Komagome Hospital Tokyo, Japan 收起 <<
NCT01764477	Advanced Pancreatic Cancer ... 展开 >> Metastatic Pancreatic Cancer Pancreatic Adenocarcinoma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California, San Francisco San Francisco, California, United States, 94115 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Washington University of Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 收起 <<
NCT03620474	Hepatitis C H... 展开 >>epatitis B Liver Cirrhoses 收起 <<	Phase 1 Phase 2	Recruiting	July 2020	Japan ... 展开 >> Tokyo Metropolitan Komagome Hospital Recruiting Bunkyō-Ku, Tokyo, Japan, 113-8677 Contact: Kiminori Kimura +81-3-3823-2101 kkimura@cick.jp Contact: Akemi Ikoma +81-3-3823-2101 ikomaakm@cick.jp 收起 <<
NCT01302405	Advanced Solid Tumors	Phase 1	Terminated(closing due to low ... 展开 >>enrollment, no safety issues) 收起 <<	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale, Arizona, United States, 85259-5499 United States, California University of Southern California, Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Minnesota Mayo Clinic, Department of Oncology Rochester, Minnesota, United States, 55901 收起 <<

Foscenvivint 99%+

Foscenvivint 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Foscenvivint 质控信息

Foscenvivint 生物活性

Foscenvivint 临床研究

Foscenvivint 实验方案

Foscenvivint 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Foscenvivint 99%+

Foscenvivint 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Foscenvivint 质控信息

Foscenvivint 生物活性

Foscenvivint 临床研究

Foscenvivint 实验方案

Foscenvivint 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Foscenvivint 纯度/质量文件产品仅供科研